Multiple antigen peptide vaccines against Plasmodium falciparum malaria

Infection and Immunity

Volumn 78, Issue 11, 2010, Pages 4613-4624

  Mahajan, Babita ^a   Berzofsky, Jay A ^b   Boykins, Robert A ^a   Majam, Victoria ^a   Zheng, Hong ^a   Chattopadhyay, Rana ^a   De La Vega, Patricia ^c   Moch, J Kathleen ^c   Haynes, J David ^c   Belyakov, Igor M ^b,d   Nakhasi, Hira L ^a   Kumar, Sanjai ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

^d MIDWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MALARIA VACCINE; PARASITE ANTIBODY; PARASITE ANTIGEN; PEPTIDE ANTIBODY; PEPTIDE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIMICROBIAL ACTIVITY; APICOMPLEXAN LIFE CYCLE STAGE; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ERYTHROCYTE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOGENICITY; LIVER CELL; MALARIA FALCIPARUM; MOUSE; MOUSE STRAIN; NONHUMAN; PARASITE IMMUNITY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE; STRAIN DIFFERENCE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DRUG DESIGN; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; ERYTHROCYTES; FEMALE; HEPATOCYTES; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, CONGENIC; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 78049423361     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00533-10     Document Type: Article

References (63)

1. Audran, R., M. Cachat, F. Lurati, S. Soe, O. Leroy, G. Corradin, P. Druilhe, and F. Spertini. 2005. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73:8017-8026.
2. Ballou, W. R., J. Rothbard, R. A. Wirtz, D. M. Gordon, J. S. Williams, R. W. Gore, I. Schneider, M. R. Hollingdale, R. L. Beaudoin, W. L. Maloy, et al. 1985. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 228:996-999. (Pubitemid 15028388)
3. Bejon, P., J. Lusingu, A. Olotu, A. Leach, M. Lievens, J. Vekemans, S. Mshamu, T. Lang, J. Gould, M. C. Dubois, M. A. Demoitie, J. F. Stallaert, P. Vansadia, T. Carter, P. Njuguna, K. O. Awuondo, A. Malabeja, O. Abdul, S. Gesase, N. Mturi, C. J. Drakeley, B. Savarese, T. Villafana, W. R. Ballou, J. Cohen, E. M. Riley, M. M. Lemnge, K. Marsh, and L. von Seidlein. 2008. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359:2521-2532.
4. Blum-Tirouvanziam, U., C. Servis, A. Habluetzel, D. Valmori, Y. Men, F. Esposito, L. Del Nero, N. Holmes, N. Fasel, and G. Corradin. 1995. Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J. Immunol. 154:3922-3931.
5. Bongfen, S. E., P. M. Ntsama, S. Offner, T. Smith, I. Felger, M. Tanner, P. Alonso, I. Nebie, J. F. Romero, O. Silvie, R. Torgler, and G. Corradin. 2009. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27:328-335.
6. Boykins, R. A., M. Joshi, C. Syin, S. Dhawan, and H. Nakhasi. 2000. Synthesis and construction of a novel multiple peptide conjugate system: strategy for a subunit vaccine design. Peptides 21:9-17.
7. Caro-Aguilar, I., S. Lapp, J. Pohl, M. R. Galinski, and A. Moreno. 2005. Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria. Microbes Infect. 7:1324-1337. (Pubitemid 41573682)
8. Corradin, G. 2007. Peptide based malaria vaccine development: personal considerations. Microbes Infect. 9:767-771.
9. Del Giudice, G., Q. Cheng, D. Mazier, N. Berbiguier, J. A. Cooper, H. D. Engers, C. Chizzolini, A. S. Verdini, F. Bonelli, A. Pessi, et al. 1988. Immunogenicity of a non-repetitive sequence of Plasmodium falciparum circumsporozoite protein in man and mice. Immunology 63:187-191.
10. Del Giudice, G., A. S. Verdini, M. Pinori, A. Pessi, J.-P. Verhave, C. Tougne, B. Ivanoff, P.-H. Lambert, and H. D. Engers. 1987. Detection of human antibodies against Plasmodium falciparum sporozoites using synthetic peptides. J. Clin. Microbiol. 25:91-96.
11. del Guercio, M. F., J. Sidney, G. Hermanson, C. Perez, H. M. Grey, R. T. Kubo, and A. Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154:685-693.
12. Doolan, D. L., S. L. Hoffman, S. Southwood, P. A. Wentworth, J. Sidney, R. W. Chesnut, E. Keogh, E. Appella, T. B. Nutman, A. A. Lal, D. M. Gordon, A. Oloo, and A. Sette. 1997. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7:97-112.
13. Doolan, D. L., S. Southwood, D. A. Freilich, J. Sidney, N. L. Graber, L. Shatney, L. Bebris, L. Florens, C. Dobano, A. A. Witney, E. Appella, S. L. Hoffman, J. R. Yates III, D. J. Carucci, and A. Sette. 2003. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc. Natl. Acad. Sci. U. S. A. 100:9952-9957.
14. Egan, J. E., J. L. Weber, W. R. Ballou, M. R. Hollingdale, W. R. Majarian, D. M. Gordon, W. L. Maloy, S. L. Hoffman, R. A. Wirtz, I. Schneider, et al. 1987. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 236:453-456.
15. Fidock, D. A., H. Gras-Masse, J. P. Lepers, K. Brahimi, L. Benmohamed, S. Mellouk, C. Guerin-Marchand, A. Londono, L. Raharimalala, J. F. Meis, et al. 1994. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J. Immunol. 153:190-204.
16. Freund, J., H. E. Sommer, and A. W. Walter. 1945. Immunization against malaria: vaccination of ducks with killed parasites incorporated with adjuvants. Science 102:200-202.
17. Good, M. F., J. A. Berzofsky, W. L. Maloy, Y. Hayashi, N. Fujii, W. T. Hockmeyer, and L. H. Miller. 1986. Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread non-responsiveness to single malaria T epitope in highly repetitive vaccine. J. Exp. Med. 164:655-660.
18. Good, M. F., J. A. Berzofsky, and L. H. Miller. 1988. The T cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development. Annu. Rev. Immunol. 6:663-688.
19. Good, M. F., W. L. Maloy, M. N. Lunde, H. Margalit, J. L. Cornette, G. L. Smith, B. Moss, L. H. Miller, and J. A. Berzofsky. 1987. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 235:1059-1062.
20. Haynes, J. D., J. K. Moch, and D. S. Smoot. 2002. Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA. Methods Mol. Med. 72:535-554.
21. Herrington, D. A., D. F. Clyde, G. Losonsky, M. Cortesia, J. R. Murphy, J. Davis, S. Baqar, A. M. Felix, E. P. Heimer, D. Gillessen, et al. 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328:257-259.
22. Hill, A. V., C. E. Allsopp, D. Kwiatkowski, N. M. Anstey, P. Twumasi, P. A. Rowe, S. Bennett, D. Brewster, A. J. McMichael, and B. M. Greenwood. 1991. Common west African HLA antigens are associated with protection from severe malaria. Nature 352:595-600.
23. Hill, A. V., J. Elvin, A. C. Willis, M. Aidoo, C. E. Allsopp, F. M. Gotch, X. M. Gao, M. Takiguchi, B. M. Greenwood, A. R. Townsend, et al. 1992. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360:434-439.
24. Hoffman, S. L., P. F. Billingsley, E. James, A. Richman, M. Loyevsky, T. Li, S. Chakravarty, A. Gunasekera, M. Li, R. Stafford, A. Ahumada, J. E. Epstein, M. Sedegah, S. Reyes, T. L. Richie, K. E. Lyke, R. Edelman, M. Laurens, C. V. Plowe, and B. K. Sim. 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6:97-106.
25. Howard, R. F., K. C. Jacobson, E. Rickel, and J. Thurman. 1998. Analysis of inhibitory epitopes in the Plasmodium falciparum rhoptry protein RAP-1 including identification of a second inhibitory epitope. Infect. Immun. 66:380-386.
26. Jalloh, A., M. Jalloh, and H. Matsuoka. 2009. T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution? Malar. J. 8:120.
27. Joshi, M. B., A. A. Gam, R. A. Boykins, S. Kumar, J. Sacci, S. L. Hoffman, H. L. Nakhasi, and R. T. Kenney. 2001. Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates. Infect. Immun. 69:4884-4890.
28. Luty, A. J., B. Lell, R. Schmidt-Ott, L. G. Lehman, D. Luckner, B. Greve, P. Matousek, K. Herbich, D. Schmid, F. Migot-Nabias, P. Deloron, R. S. Nussenzweig, and P. G. Kremsner. 1999. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 179:980-988.
29. Lyke, K. E., R. B. Burges, Y. Cissoko, L. Sangare, A. Kone, M. Dao, I. Diarra, M. A. Fernandez-Vina, C. V. Plowe, O. K. Doumbo, and M. B. Sztein. 2005. HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. Infect. Immun. 73:5799-5808.
30. McCutchan, T. F., J. C. Kissinger, M. G. Touray, M. J. Rogers, J. Li, M. Sullivan, E. M. Braga, A. U. Krettli, and L. H. Miller. 1996. Comparison of circumsporozoite proteins from avian and mammalian malarias: biological and phylogenetic implications. Proc. Natl. Acad. Sci. U. S. A. 93:11889-11894.
31. Moreno, C. A., R. Rodriguez, G. A. Oliveira, V. Ferreira, R. S. Nussenzweig, Z. R. Moya Castro, J. M. Calvo-Calle, and E. Nardin. 1999. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice. Vaccine 18:89-99.
32. Nardin, E. 2010. The past decade in malaria synthetic peptide vaccine clinical trials. Hum. Vaccin. 6:27-38.
33. Nardin, E. H., D. A. Herrington, J. Davis, M. Levine, D. Stüber, B. Takacs, P. Caspers, P. Barr, R. Altszuler, P. Clavijo, et al. 1989. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science 246:1603-1606.
34. Nardin, E. H., G. A. Oliveira, J. M. Calvo-Calle, Z. R. Castro, R. S. Nussenzweig, B. Schmeckpeper, B. F. Hall, C. Diggs, S. Bodison, and R. Edelman. 2000. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182:1486-1496.
35. Oeuvray, C., H. Bouharoun-Tayoun, H. Gras-Masse, E. Bottius, T. Kaidoh, M. Aikawa, M. C. Filgueira, A. Tartar, and P. Druilhe. 1994. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84:1594-1602. (Pubitemid 24273030)
36. Oeuvray, C., H. Bouharoun-Tayoun, H. Grass-Masse, J. P. Lepers, L. Ralamboranto, A. Tartar, and P. Druilhe. 1994. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem. Inst. Oswaldo Cruz 89(Suppl. 2):77-80.
37. Overstreet, M. G., I. A. Cockburn, Y. C. Chen, and F. Zavala. 2008. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol. Rev. 225:272-283.
38. Ozaki, L. S., R. W. Gwadz, and G. N. Godson. 1984. Simple centrifugation method for rapid separation of sporozoites from mosquitoes. J. Parasitol. 70:831-833.
39. Perlaza, B. L., J. P. Sauzet, A. T. Balde, K. Brahimi, A. Tall, G. Corradin, and P. Druilhe. 2001. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur. J. Immunol. 31:2200-2209.
40. Potocnjak, P., N. Yoshida, R. S. Nussenzweig, and V. Nussenzweig. 1980. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151:1504-1513.
41. Puentes, A., J. Garcia, R. Vera, Q. R. Lopez, M. Urquiza, M. Vanegas, L. M. Salazar, and M. E. Patarroyo. 2000. Serine repeat antigen peptides which bind specifically to red blood cells. Parasitol. Int. 49:105-117.
42. Quang, N. D., P. T. Hoa, M. S. Tuan, N. X. Viet, A. Jalloh, and H. Matsuoka. 2009. Polymorphism at the apical membrane antigen 1 gene (AMA1) of the malaria parasite Plasmodium falciparum in a Vietnamese population. Biochem. Genet. 47:370-383.
43. Riley, E. M., O. Olerup, S. Bennett, P. Rowe, S. J. Allen, M. J. Blackman, M. Troye-Blomberg, A. A. Holder, and B. M. Greenwood. 1992. MHC and malaria: the relationship between HLA class II alleles and immune responses to Plasmodium falciparum. Int. Immunol. 4:1055-1063.
44. Sattabongkot, J., N. Yimamnuaychoke, S. Leelaudomlipi, M. Rasameesoraj, R. Jenwithisuk, R. E. Coleman, R. Udomsangpetch, L. Cui, and T. G. Brewer. 2006. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 74:708-715.
45. Shi, Y. P., P. Das, B. Holloway, V. Udhayakumar, J. E. Tongren, F. Candal, S. Biswas, R. Ahmad, S. E. Hasnain, and A. A. Lal. 2000. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine 18:2902-2914.
46. Shi, Y. P., S. E. Hasnain, J. B. Sacci, B. P. Holloway, H. Fujioka, N. Kumar, R. Wohlhueter, S. L. Hoffman, W. E. Collins, and A. A. Lal. 1999. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. U. S. A. 96:1615-1620.
47. Shi, Y. P., V. Udhayakumar, M. P. Alpers, M. M. Povoa, A. J. Oloo, T. K. Ruebush II, and A. A. Lal. 1993. Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein. Infect. Immun. 61:2425-2433.
48. Silva-Flannery, L. M., M. Cabrera-Mora, M. Dickherber, and A. Moreno. 2009. Polymeric linear peptide chimeric vaccine-induced antimalaria immunity is associated with enhanced in vitro antigen loading. Infect. Immun. 77:1798-1806.
49. Silva-Flannery, L. M., M. Cabrera-Mora, J. Jiang, and A. Moreno. 2009. Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine. Microbes Infect. 11:83-91.
50. Singh, S., S. Soe, J. P. Mejia, C. Roussilhon, M. Theisen, G. Corradin, and P. Druilhe. 2004. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J. Infect. Dis. 190:1010-1018.
51. Stephens, H. A., A. E. Brown, D. Chandanayingyong, H. K. Webster, M. Sirikong, P. Longta, R. Vangseratthana, D. M. Gordon, S. Lekmak, and E. Rungruang. 1995. The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen. Eur. J. Immunol. 25:3142-3147.
52. Stowers, A. W., J. A. Cooper, T. Ehrhardt, and A. Saul. 1996. A peptide derived from a B cell epitope of Plasmodium falciparum rhoptry associated protein 2 specifically raises antibodies to rhoptry associated protein 1. Mol. Biochem. Parasitol. 82:167-180.
53. Stüber, D., W. Bannwarth, J. R. Pink, R. H. Meloen, and H. Matile. 1990. New B cell epitopes in the Plasmodium falciparum malaria circumsporozoite protein. Eur. J. Immunol. 20:819-824.
54. Takala, S. L., D. Coulibaly, M. A. Thera, A. H. Batchelor, M. P. Cummings, A. A. Escalante, A. Ouattara, K. Traore, A. Niangaly, A. A. Djimde, O. K. Doumbo, and C. V. Plowe. 2009. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med. 1:2ra5.
55. Takala, S. L., and C. V. Plowe. 2009. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol. 31:560-573.
56. Tam, J. P., P. Clavijo, Y. A. Lu, V. Nussenzweig, R. Nussenzweig, and F. Zavala. 1990. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 171:299-306.
57. Udhayakumar, V., D. Anyona, S. Kariuki, Y. P. Shi, P. B. Bloland, O. H. Branch, W. Weiss, B. L. Nahlen, D. C. Kaslow, and A. A. Lal. 1995. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J. Immunol. 154:6022-6030.
58. Urquiza, M., L. E. Rodriguez, J. E. Suarez, F. Guzman, M. Ocampo, H. Curtidor, C. Segura, E. Trujillo, and M. E. Patarroyo. 1996. Identification of Plasmodium falciparum MSP-1 peptides able to bind to human red blood cells. Parasite Immunol. 18:515-526.
59. Vaughan, A. M., R. Wang, and S. H. Kappe. 2010. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum. Vaccin. 6:107-113.
60. Vaughan, K., M. Blythe, J. Greenbaum, Q. Zhang, B. Peters, D. L. Doolan, and A. Sette. 2009. Meta-analysis of immune epitope data for all plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol. 31:78-97.
61. Wang, R., Y. Charoenvit, G. Corradin, R. Porrozzi, R. L. Hunter, G. Glenn, C. R. Alving, P. Church, and S. L. Hoffman. 1995. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 154:2784-2793.
62. Young, J. F., W. T. Hockmeyer, M. Gross, W. R. Ballou, R. A. Wirtz, J. H. Trosper, R. L. Beaudoin, M. R. Hollingdale, L. H. Miller, C. L. Diggs, et al. 1985. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science 228:958-962.
63. Zavala, F., J. P. Tam, M. R. Hollingdale, A. H. Cochrane, I. Quakyi, R. S. Nussenzweig, and V. Nussenzweig. 1985. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228:1436-1440. (Pubitemid 15041321)